Table 3. Mortality rate ratio (MRR) of HIV-infected individuals initiating HAART after 1 January 1998 with a VL <50 copies/ml within 180 days of HAART initiation with censoring of individuals with virological failure (VL >500copies/ml) comparing time on statin with time not on statin.
| CENSORED AT DATE OF VIROLOGICAL FAILURE | |||||
| (VL >500 copies/ml) (Model A) | |||||
| MRR (95%CI) | |||||
| STATIN USE (time-updated variable) | No. of Deaths | PYR | MR per 1,000 PYR (95% CI) | Unadjusted | Adjusted |
| Adjustment 1: * | |||||
| No use of or time before initiation of a statin drug | 102 | 7,528 | 13.55 (11.16–16.45) | Ref (1) | Ref (1) |
| Use of or time after initiation of a statin drug | 7 | 424 | 16.52 (7.88–34.66) | 1.22 (0.57–2.62) | 0.75 (0.33–1.68) |
| Adjustment 2: * | |||||
| BEFORE OR NO DIAGNOSIS OF COMORBIDITY: | |||||
| No use of or time before initiation of a statin drug | 84 | 7,138 | 11.77 (9.50–14.57) | Ref (1) | Ref (1) |
| Use of or time after initiation of a statin drug | 3 | 184 | 16.33 (5.27–50.62) | 1.39 (0.44–4.39) | 1.12 (0.34–3.62) |
| AFTER A DIAGNOSIS OF COMORBIDITY: | |||||
| No use of or time before initiation of a statin drug | 18 | 390 | 46.11 (29.05–73.19) | Ref (1) | Ref (1) |
| Use of or time after initiation of a statin drug | 4 | 240 | 16.67 (6.26–44.42) | 0.36 (0.12–1.07) | 0.34 (0.11–1.04) |
Abbreviations: MRM: Mortality Rate Ratio; 95% CI: 95% Confidence Interval; PYR: Person years of follow-up; MSM: men who have sex with men; HAART: Highly Active Antiretroviral Therapy.
Adjustment 1: Adjusted for age (treated as time-updated variables split at 30, 40, 50, 60,70), gender, race, HIV transmission group, CD4 cell count at HAART initiation (<50, 50–200, >200 cells/µl), HIV VL at HAART initiation (log10 VL), total cholesterol (<5, 5–8, >8, missing values), year of HAART initiation (<2004 vs. > = 2004), ART prior to HAART, AIDS defining illness prior to HAART initiation, Viral hepatitis C co-infection.
Adjustment 2: Adjusted for variables as in model 1 + comorbidity and the clinically important interaction between comorbidity and statin use/non-use, The MRRs are therefore presented both before and after development of a comorbid condition. Comorbidity is defined as the first of the following comorbid conditions: coronary artery disease, cerebrovascular disease, peripheral artery disease, chronic kidney disease and a redeemed prescription of an antidiabetic drug and introduced as a time-updated variable.